Current developments in the treatment of peanut allergy

被引：0

作者：

Worm M. ^{[1
]}

Francuzik W. ^{[1
]}

Dölle S. ^{[1
]}

Lange L. ^{[2
]}

Alexiou A. ^{[1
]}

机构：

[1] Allergologie und Immunologie, Klinik für Dermatologie und Allergologie Campus Mitte, Charité—Universitätsmedizin Berlin, Charitéplatz 1, Berlin

[2] Abteilung für Kinder- und Jugendmedizin, St. Marien-Hospital, Bonn

来源：

Allergo Journal International | 2021年 / 30卷 / 2期

关键词：

Anaphylaxis; Anti-immunoglobulin E; Dupilumab; Immunotherapy; Peanut allergy;

D O I：

10.1007/s40629-021-00164-8

中图分类号：

学科分类号：

摘要：

Peanut allergy is a potentially life-threatening disease because it leads to severe allergic reactions, especially in children but also in adults. So far, allergen avoidance is the most effective therapy for treating peanut allergy. In this article, current developments of peanut allergy specific immunotherapy are critically discussed based on the existing literature. These include sublingual, epicutaneous and oral peanut immunotherapy. Nonspecific treatment approaches with new-targeted antibodies such as anti-IgE (omalizumab) or anti-IL-4/IL-13 receptor antibodies (dupilumab) can also be used to treat peanut allergy with regard to the mode of action of these antibodies. Multiple studies are already available for omalizumab and are currently performed with dupilumab. Whether and which therapies for the treatment of peanut allergy will be available on the market in the future is not only relevant in terms of clinical effectiveness in the sense of a long-term stable increase in the threshold level, but also in terms of the tolerability in everyday life of affected patients. © 2021, The Author(s).

引用

页码：56 / 63

页数：7

共 48 条

[1]

Worm M., Eckermann O., Dolle S., Aberer W., Beyer K., Hawranek T., Et al., Triggers and treatment of anaphylaxis: an analysis of 4,000 cases from Germany, Austria and Switzerland, Dtsch Arztebl Int, 111, pp. 367-375, (2014)

[2]

Bergmann K.C., Heinrich J., Niemann H., Current status of allergy prevalence in germany. Position paper of the environmental medicine commission of the Robert Koch Institute, Allergo J Int, 25, pp. 6-10, (2016)

[3]

Nwaru B.I., Hickstein L., Panesar S.S., Muraro A., Werfel T., Cardona V., Et al., The epidemiology of food allergy in Europe: a systematic review and meta-analysis, Allergy, 69, pp. 62-75, (2014)

[4]

Grabenhenrich L., Trendelenburg V., Bellach J., Yurek S., Reich A., Fiandor A., Et al., Frequency of food allergy in school-aged children in eight European countries—the EuroPrevall-iFAAM birth cohort, Allergy, 75, pp. 2294-2308, (2020)

[5]

Schoemaker A.A., Sprikkelman A.B., Grimshaw K.E., Roberts G., Grabenhenrich L., Rosenfeld L., Et al., Incidence and natural history of challenge-proven cow’s milk allergy in European children—EuroPrevall birth cohort, Allergy, 70, pp. 963-972, (2015)

[6]

Xepapadaki P., Fiocchi A., Grabenhenrich L., Roberts G., Grimshaw K.E.C., Fiandor A., Et al., Incidence and natural history of hen’s egg allergy in the first 2 years of life—the EuroPrevall birth cohort study, Allergy, 71, pp. 350-357, (2016)

[7]

Peters R.L., Allen K.J., Dharmage S.C., Koplin J.J., Dang T., Tilbrook K.P., Et al., Natural history of peanut allergy and predictors of resolution in the first 4 years of life: A population-based assessment, J Allergy Clin Immunol, 135, pp. 1257-1266, (2015)

[8]

Maris I., Dolle S., Renaudin J.-M., Lange L., Koehli A., Spindler T., Et al., Peanut induced anaphylaxis in children and adolescents: data from the European Anaphylaxis Registry, Allergy, (2020)

[9]

Worm M., Reese I., Ballmer-Weber B., Beyer K., Bischoff S.C., Classen M., Et al., Guidelines on the management of IgE-mediated food allergies: S2k-Guidelines of the German Society for Allergology and Clinical Immunology (DGAKI) in collaboration with the German Medical Association of Allergologists (AeDA), the German Professional Association of Pediatricians (BVKJ), the German Allergy and Asthma Association (DAAB), German Dermatological Society (DDG), the German Society for Nutrition (DGE), the

[10]

Kukkonen A.K., Pelkonen A.S., Makinen-Kiljunen S., Voutilainen H., Makela M.J., Ara h 2 and Ara 6 are the best predictors of severe peanut allergy: a double-blind placebo-controlled study, Allergy, 70, pp. 1239-1245, (2015)

← 1 2 3 4 5 →